A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

Citation record

Study start

2026-03-26

NCT number

NCT07293351

Phase

Phase1, Phase2

Overall status

Recruiting

Study type

Interventional

Lead sponsor

Bristol-Myers Squibb

Enrollment

474 participants

Conditions

Advanced Renal Cell Carcinoma (RCC)

Interventions

Pumitamig (Drug) · Ipilimumab (Drug) · Cabozantinib (Drug) · Casdatifan (Drug)

Last updated at source

23 Oct 2026

Original source

https://clinicaltrials.gov/study/NCT07293351

This page reproduces citation metadata only. Inclusion in the Avion Science research library does not imply endorsement and does not establish the safety, efficacy or intended use of any Avion Science compound. Refer to the original record for complete study information.